Search
RBC Healthcare Conference: After meeting with FDA numerous times over the last six months, MoonLake is preparing to file its BLA for sonelokimab in the fall
Founder, Chairman & CEO Jorge Santos da Silva walks us through the pivotal and other supporting data he believes makes this a compelling option in HA, and discusses preparations to file and beyond.
2 hours ago
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and...
Jul 10, 2025
London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
Jorge Santos da Silva explains the properties that he believes give Nanobodies versatility and an edge over traditional antibodies, and...
Nov 18, 2024
.png){kind=logo}
